10X Genomics, Inc. (TXG)
| Market Cap | 18.48B |
| Revenue (ttm) | 261.92M |
| Net Income (ttm) | -134.29M |
| Shares Out | 101.34M |
| EPS (ttm) | -5.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $169.92 |
| Previous Close | $171.75 |
| Change ($) | -1.83 |
| Change (%) | -1.07% |
| Day's Open | 170.00 |
| Day's Range | 161.13 - 172.59 |
| Day's Volume | 420,928 |
| 52-Week Range | 51.57 - 187.00 |
10X Genomics Strategy Driven By Innovation, CEO Says
Jan.12 -- 10X Genomics Inc. Chief Executive Officer Serge Saxonov discusses the company's strategy and performance amid the Covid-19 pandemic with Bloomberg's Vonnie Quinn on "Bloomberg Markets."
PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Co...
10X Genomics is a cutting edge, single-cell assay hardware, software and consumables company. Don't feel bad, I don't understand all of that either.
Here's how these big businesses became enormous during a year most of us would rather forget.
10X Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Earnings Call Transcript
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Quick Version Earnings Call Transcript
10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.
PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, Nove...
10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.
Covid-19 Vaccine Likely Early 2021, Says 10x Genomics CEO
Oct.07 -- Serge Saxonov, co-founder and chief executive officer at 10x Genomics Inc., discusses developments on a vaccine for Covid-19 on "Bloomberg Technology."
Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB
10x Genomics, Inc. has performed outstandingly well since the COVID-19 induced lows of March, more than doubling in this time.
PLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A ...
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company ...
PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,50...
These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?
PLEASANTON, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2020 Results - Earnings Call Transcript
PLEASANTON, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2020.
PLEASANTON, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Vi...
10x Genomics is growing fast and likely to become a successful life science tools company.
Delivers major improvements for discoveries in immunology, oncology, autoimmunity, and infectious diseases Delivers major improvements for discoveries in immunology, oncology, autoimmunity, an...
GSK, Johns Hopkins Medical Institutions, Mass General Cancer Center join global network to accelerate discoveries in COVID-19, oncology, immuno-oncology and neurology GSK, Johns Hopkins Medica...
10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
New solution accelerates research validation in cancer, immunology and drug discovery New solution accelerates research validation in cancer, immunology and drug discovery
Pioneering Effort for Safe Workplace Reentry Pioneering Effort for Safe Workplace Reentry
Pioneering Effort for Safe Workplace Reentry Pioneering Effort for Safe Workplace Reentry
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2020 Results - Earnings Call Transcript
Provides Preliminary Revenue Range for the First Quarter 2020
Covid-19 Therapeutics Will Be Available Before a Vaccine, Says 10x Genomics CEO
10x Genomics Chief Executive Officer Sergei Samsonov and Bloomberg's Michelle Cortez discuss the race to find a cure for Covid-19. They speak with Bloomberg's Emily Chang on "Bloomberg Technol...
Former Genomic Health CEO brings decades of healthcare experience to Board Former Genomic Health CEO brings decades of healthcare experience to Board
Ships Chromium Connect; Unveils Dozen New Applications to Advance Genomics Ships Chromium Connect; Unveils Dozen New Applications to Advance Genomics
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2019 Results - Earnings Call Transcript
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
The company scored an important win in a patent dispute.
10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility pos...
First Product Developed from Spatial Transcriptomics Acquisition First Product Developed from Spatial Transcriptomics Acquisition
10x Genomics Inc. (TXG) CEO Serge Saxonov on Q3 2019 Results - Earnings Call Transcript
10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.
PLEASANTON, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock,...
Single-Cell Analysis Breakthroughs Have Been Incredible, 10X Genomics CEO Says
10X Genomics Inc. Chief Executive Officer Serge Saxonov discusses the company's single-cell analysis technology with Bloomberg's Taylor Riggs on "Bloomberg Technology."
10x Genomics CEO Serge Saxonov on company's first trade
CEO of 10x Genomics Serge Saxonov discusses his thoughts on the company's growth and competition with "Squawk Alley".
10X Genomics Inc. (NASDAQ: TXG) shares entered the market with a bang on Thursday.
SmileDirectClub, 10x Genomics set to IPO at the Nasdaq
CNBC's Leslie Picker takes a look at two IPOs, 10x Genomics and SmileDirectClub, set to debut at the Nasdaq today.
About TXG
10x Genomics, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the ... [Read more...]
| Industry Health Information Services | IPO Date Sep 12, 2019 |
| CEO Serge Saxonov | Employees 584 |
| Stock Exchange NASDAQ | Ticker Symbol TXG |
Financial Performance
In 2019, 10X Genomics's revenue was $245.89 million, an increase of 68.06% compared to the previous year's $146.31 million. Losses were -$31.25 million, -72.22% less than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for 10X Genomics stock is "Buy." The 12-month stock price forecast is 157.50, which is a decrease of -7.31% from the latest price.